Print

Acorda Therapeutics (ACOR) Has a Hard Time Following Instructions: FDA  
8/9/2013 6:45:22 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Once again, Acorda Therapeutics has run afoul of the FDA. The drugmaker has now racked up three letters – two of which were warning letters - from the agency in little more than a year. The latest infraction, in fact, marks the second time during this stretch that Acorda has been scolded for improperly advertising its Ampyra treatment for improving walking in people with multiple sclerosis. In the newest warning letter, the FDA tagged Acorda for a newspaper ad that omitted all risk information – contraindications, warnings, precautions and the most frequently reported adverse events.

Help employers find you! Check out all the jobs and post your resume.

//-->